Jewell Christopher M

SEC source: 0001453687-25-000045 · wk-form4_1736802540.xml · derivative · entry 2

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,432

Underlying: Common Stock · 9,000 shares

Expires 2033-01-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F1 · derivative.exercise_date: The option is currently exercisable for an additional 51,089 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until it is fully exercisable on June 16, 2025.

SEC source: 0001453687-25-000045 · wk-form4_1736802540.xml · nonDerivative · entry 1

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,490

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-25-000038 · wk-form4_1736298315.xml · nonDerivative · entry 2

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,490

F1 · price: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.

SEC source: 0001453687-25-000038 · wk-form4_1736298315.xml · nonDerivative · entry 1

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,776

F1 · price: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.

SEC source: 0001453687-25-000027 · wk-form4_1736198467.xml · derivative · entry 2

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,400

Underlying: Common Stock · 47,400 shares

Expires 2035-01-01

F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029.

SEC source: 0001453687-25-000027 · wk-form4_1736198467.xml · nonDerivative · entry 1

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,040

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029.

SEC source: 0001453687-24-000138 · wk-form4_1732233005.xml · derivative · entry 2

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,432

Underlying: Common Stock · 14,000 shares

Expires 2033-01-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F1 · derivative.exercise_date: The option is currently exercisable for 123,235 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until it is fully exercisable on June 16, 2025.

SEC source: 0001453687-24-000138 · wk-form4_1732233005.xml · nonDerivative · entry 1

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,940

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000128 · wk-form4_1731975821.xml · derivative · entry 7

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,432

Underlying: Common Stock · 16,065 shares

Expires 2033-01-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F4 · derivative.exercise_date: The option is currently exercisable for 123,235 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until it is fully exercisable on June 16, 2025.

SEC source: 0001453687-24-000128 · wk-form4_1731975821.xml · nonDerivative · entry 5

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,940

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.24. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000128 · wk-form4_1731975821.xml · nonDerivative · entry 4

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,005

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000128 · wk-form4_1731975821.xml · derivative · entry 6

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,497

Underlying: Common Stock · 36,050 shares

Expires 2033-01-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F4 · derivative.exercise_date: The option is currently exercisable for 123,235 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until it is fully exercisable on June 16, 2025.

SEC source: 0001453687-24-000128 · wk-form4_1731975821.xml · nonDerivative · entry 3

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,940

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.18. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000128 · wk-form4_1731975821.xml · nonDerivative · entry 2

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,440

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.00 to $16.89. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000128 · wk-form4_1731975821.xml · nonDerivative · entry 1

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,990

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000061 · wk-form4_1712799327.xml · derivative · entry 3

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,547

Underlying: Common Stock · 142,547 shares

Expires 2033-01-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Following the Automatic Conversion, options previously exercisable for shares of Series A Preferred Stock may be exercised solely for shares of Common Stock.

F4 · derivative.exercise_date: Following the Automatic Conversion, the option is currently exercisable for 99,483 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until is is fully exercisable on June 16, 2025.

F1 · derivative.underlying_shares: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split (the "Reverse Stock Split") of its common stock ("Common Stock"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

F1 · balance_after: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split (the "Reverse Stock Split") of its common stock ("Common Stock"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001453687-24-000061 · wk-form4_1712799327.xml · derivative · entry 2

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Series A Non-Voting Convertible Preferred Stock · 4,276.454 shares

Expires 2033-01-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: On November 13, 2023, the issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of Series A Preferred Stock in connection with the acquisition.

F2 · derivative.exercise_date: On March 27, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved the Reverse Stock Split and the conversion of the issuer's Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") into shares of Common Stock. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. Prior to the Automatic Conversion, the option was exercisable for 2,984.676 shares of Series A Non-Voting Convertible Preferred Stock of the issuer ("Series A Preferred Stock") and would have become exercisable for an additional 89.093 shares each month until it was fully exercisable on June 16, 2025.

SEC source: 0001453687-24-000026 · wk-form4_1704406063.xml · derivative · entry 2

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 998,000

Underlying: Common Stock · 998,000 shares

Expires 2034-01-01

F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028.

SEC source: 0001453687-24-000026 · wk-form4_1704406063.xml · nonDerivative · entry 1

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 778,200

F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028.

SEC source: 0001062993-23-020923 · form4.xml · derivative · entry 1

Jewell Christopher M · CIK 0002000226 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,276.454

Underlying: Series A Non-Voting Convertible Preferred Stock · 4,276.454 shares

Expires 2033-01-15

F3 · price: On November 13, 2023, the issuer acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Cartesian common stock held by the reporting person were converted into options to purchase shares of Series A Preferred Stock in connection with the acquisition.

F1 · derivative.exercise_date: Option is currently exercisable for 2,539.177 shares of Series A Non-Voting Convertible Preferred Stock of the issuer ("Series A Preferred Stock") and becomes exercisable for an additional 89.093 shares each month until it is fully exercisable.

F2 · derivative.underlying: Following the approval by the stockholders of the issuer of the conversion of the Series A Preferred Stock into shares of common stock of the issuer ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.